Abstract
.Significance: Major depressive disorder (MDD) affects over 40 million U.S. adults in their lifetime. Transcranial photobiomodulation (t-PBM) has been shown to be effective in treating MDD, but the current treatment dosage does not account for head and brain anatomical changes due to aging.Aim: We study effective t-PBM dosage and its variations across age groups using state-of-the-art Monte Carlo simulations and age-dependent brain atlases ranging between 5 and 85 years of age.Approach: Age-dependent brain models are derived from 18 MRI brain atlases. Two extracranial source positions, F3–F4 and Fp1–Fpz–Fp2 in the EEG 10–20 system, are simulated at five selected wavelengths and energy depositions at two MDD-relevant cortical regions—dorsolateral prefrontal cortex (dlPFC) and ventromedial prefrontal cortex (vmPFC)—are quantified.Results: An overall decrease of energy deposition was found with increasing age. A strong negative correlation between the thickness of extracerebral tissues (ECT) and energy deposition was observed, suggesting that increasing ECT thickness over age is primarily responsible for reduced energy delivery. The F3–F4 position appears to be more efficient in reaching dlPFC compared to treating vmPFC via the Fp1–Fpz–Fp2 position.Conclusions: Quantitative simulations revealed age-dependent light delivery across the lifespan of human brains, suggesting the need for personalized and age-adaptive t-PBM treatment planning.
Highlights
According to the U.S National Institutes of Health,[1] the estimated lifetime prevalence of major depressive disorder (MDD) in the United States comprises over 13% of the population
We systematically investigated light dosimetry in the Transcranial photobiomodulation (t-PBM) treatment across a wide span of ages
For modeling the brain anatomy, we have developed a robust workflow to create multilayered head segmentations from publicly available Neurodevelopmental magnetic resonance imaging (MRI) atlas library data
Summary
According to the U.S National Institutes of Health,[1] the estimated lifetime prevalence of major depressive disorder (MDD) in the United States comprises over 13% of the population. MDD can develop at any age and is considered the leading cause of disability in the U.S for individuals between the ages of 15 and 44 years.[2,3,4] The two most commonly used treatments for MDD are antidepressants (87.0%) and psychotherapy (23.2%).[5] Several known challenges have been faced by these treatment approaches: (1) frequent relapses of the cognitive therapy[6] and Neurophotonics. (2) burdensome side effects of antidepressant medication.[7] many patients prefer to self-manage, which leads to the low treatment rates.[8] new, effective, safe, and easy-toadminister treatment methods are needed to battle MDD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
